HR+ HER2- Early Breast Cancer (EBC) Patients ≥70 with High Risk 70-gene Signature Benefit from (Neo)adjuvant Chemotherapy (CT): Real World FLEX Study
Publication: SABCS 2025, Presentation ID: PS3-08-17 Authors: Mahtani et Read More
HR+ HER2- Early Breast Cancer (EBC) Patients ≥70 with High Risk 70-gene Signature Benefit from (Neo)adjuvant Chemotherapy (CT): Real World FLEX Study GalleryHR+ HER2- Early Breast Cancer (EBC) Patients ≥70 with High Risk 70-gene Signature Benefit from (Neo)adjuvant Chemotherapy (CT): Real World FLEX Study
